How to Reconstitute ARA-290
A laboratory guide to reconstituting ARA-290 (cibinetide), covering the compound's identifiers, its innate repair receptor target, and the clinical research models in which it has been studied.
ARA-290, also known as cibinetide, is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO) and classified as a non-hematopoietic erythropoietin analogue. It is supplied as a lyophilised powder for laboratory research use and is reconstituted with a suitable solvent before experimental handling. The published clinical literature describes ARA-290 as a peptide that does not carry the effects of EPO on blood cells, which is the property that distinguishes it from the parent hormone in research settings [4].
The work on this compound centres on the innate repair receptor, a receptor complex that ARA-290 interacts with to produce anti-apoptotic and anti-inflammatory activity across a range of cells, tissues and organs [2].
Research Studies
ARA-290 and the innate repair receptor in sarcoidosis-associated small fibre neuropathy
A phase II study examined whether ARA-290 was effective in the treatment of neuropathic symptoms in subjects with sarcoidosis. The rationale given for the trial was that brief interaction of ARA-290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in a wide range of cells, tissues and organs, activating repair mechanisms and accelerating healing, including nerve damage associated with sarcoidosis. In that study, subjects with sarcoidosis and symptoms of small fibre neuropathy received either ARA-290 or placebo by subcutaneous injection daily for 28 days, with safety monitoring alongside symptom assessment [2].
ARA-290 and diabetic macular oedema in type 1 and type 2 diabetes
The ARA 290-DMO trial was a prospective, open-label, interventional, single-centre, investigator-led phase II study designed to examine the effect of ARA-290 on diabetic macular oedema in patients with type 1 or type 2 diabetes. The primary objective was to determine whether ARA-290 administered at a daily dose of 4 mg subcutaneously for 12 weeks to patients with diabetes mellitus and diabetic macular oedema would have a beneficial effect on the mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1].
ARA-290 and glycaemic control in prediabetes and type 2 diabetes
A separate study was designed to determine whether ARA-290, described as a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose tolerance or impaired fasting glucose) or drug-naive type 2 diabetes. The same study evaluated effects on insulin sensitivity and on serum levels of inflammatory agents such as cytokines, with safety monitored through haematology, kidney and liver function parameters and lipid levels [3].
ARA-290 and cognitive and neural processing of emotion in healthy volunteers
Research on the hormone erythropoietin had indicated that EPO may have antidepressant properties, but repeated administration of EPO may cause serious side-effects such as thrombosis, which limits its usefulness in that context. ARA-290, a peptide that does not have the effects of EPO on blood cells, was studied for its possible effect on brain function. In an attempt to replicate previous findings obtained with a single dose of EPO in healthy volunteers, investigators studied the effects of ARA-290 on the cognitive and neural processing of emotions in healthy volunteers, hypothesising that a single dose would lead to a positive shift in information processing compared with placebo at 7 days post-administration [4].
ARA-290 and regenerative peptide research in tissue repair and chronic pain
A narrative review of regenerative peptides relevant to chronic pain management summarised current evidence across a group of compounds including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500) and glycyl-L-histidyl-L-lysine copper (GHK-Cu), alongside growth hormone-related peptides. This review is a reference point for the wider peptide class rather than a study of ARA-290 itself [5].
ARA-290 and the erythropoietin analogue class
Across the clinical programmes described above, ARA-290 is consistently characterised as an erythropoietin analogue engineered to retain activity at the innate repair receptor while lacking the haematopoietic effects of the parent hormone [2][3][4]. This distinction is the basis on which the compound has been selected for study in neurological, metabolic and ophthalmic models rather than in anaemia-related research.
ARA-290 and route of administration in published protocols
The clinical protocols in the evidence describe subcutaneous injection as the route of administration, with daily dosing schedules of 28 days in the sarcoidosis study [2] and 12 weeks at 4 mg daily in the diabetic macular oedema study [1]. The cognitive study in healthy volunteers used a single dose design [4]. These are descriptions of trial methodology, not handling instructions for laboratory material.
ARA-290 and study populations across the clinical literature
The populations studied differ substantially between programmes. The table below summarises the model, population and design reported for each.
| Study focus | Population | Design as reported |
|---|---|---|
| Diabetic macular oedema [1] | Patients with type 1 or type 2 diabetes and DMO | Prospective, open-label, interventional, single-centre, investigator-led phase II; 4 mg daily subcutaneous for 12 weeks |
| Sarcoidosis neuropathy [2] | Subjects with sarcoidosis and symptoms of small fibre neuropathy | ARA-290 or placebo by subcutaneous injection daily for 28 days |
| Prediabetes and type 2 diabetes [3] | Persons with prediabetes (IGT or IFG) or drug-naive type 2 diabetes | Evaluation of blood glucose, insulin secretion, insulin sensitivity and inflammatory markers |
| Cognitive and neural effects [4] | Healthy volunteers | Single dose, placebo comparison, assessment 7 days post-administration |
ARA-290 and safety monitoring in reported protocols
Safety monitoring is described in the trial records. The prediabetes and type 2 diabetes study followed haematology, kidney and liver function parameters and lipid levels [3]. The sarcoidosis study monitored safety alongside symptom outcomes [2]. The diabetic macular oedema trial reported its primary endpoint as mean change in BCVA from baseline to week 12 [1].
Handling notes for laboratory reconstitution
Reconstitution practice for research peptides follows general laboratory principles rather than compound-specific clinical guidance. The evidence block for ARA-290 does not supply a reconstitution protocol, solvent recommendation, concentration or storage specification, and none should be inferred from the clinical trial records, which describe subcutaneous administration in human subjects rather than bench handling. Researchers working with the lyophilised material should follow their institution's standard operating procedures for peptide handling and the documentation supplied with the specific lot.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema — https://clinicaltrials.gov/study/NCT06626971
- [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis — https://clinicaltrials.gov/study/NCT02039687
- [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes — https://clinicaltrials.gov/study/NCT01933529
- [4] Cognitive and Neural Effects of ARA290 — https://clinicaltrials.gov/study/NCT02070783
- [5] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management — https://pubmed.ncbi.nlm.nih.gov/42635865/